Testing a new hepatitis B pill (GST-HG131) for chronic HBV
Part of Digestive system, Infections clinical trials.
This study tests a new drug, GST-HG131, for people with chronic hepatitis B who are already on stable treatment. It aims to see if the drug is safe and reduces the virus further.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Aged 35 to 65 years
- On stable hepatitis B treatment (nucleoside analog) for at least 6 months, with no change in the last 3 months
- Your hepatitis B virus level is very low (undetectable by a standard test) for at least a month
- You are HBeAg negative and your HBsAg level is between 100 and 1500 IU/mL
- Your liver enzymes (ALT) are within normal range
- No history of cirrhosis or liver cancer, and no other major liver disease
- No active infections, serious health conditions, or recent major surgery
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment (GST-HG131&141 tablets) versus a placebo for people with chronic hepatitis B. It aims to see if the treatment can better control the virus in those already on stable therapy.
This trial tests a new injection called AHB-137 for people with chronic hepatitis B. It aims to see if the drug is safe and helps control the virus.
This trial tests a new drug called GST-HG141 for people with chronic hepatitis B whose virus is still active despite taking standard antiviral pills. It aims to see if the new drug can better control the virus.
This trial is for people who have already completed a previous study of the drug GST-HG141 (Nairevir) and are now continuing with the same drug plus a nucleoside analog (a standard antiviral). It aims to see how safe and effective this combination is over a longer period.
This study tests a new medicine called ZM-H1505R for people with chronic hepatitis B who are already taking standard antiviral therapy. It aims to see if the new drug can help control the infection better.
This trial tests a new investigational drug called AHB-171 for people with chronic hepatitis B who are already stable on standard antiviral therapy. It aims to see if the drug is safe and may help control the virus better.
Hear when a new Chronic Hepatitis B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.